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Background: The goal of this study is to explore the effects of A-W MGC (apatite-wollastonite magnetic bioactive
glass-ceramic) loaded with BMP2 (bone morphogenetic protein 2)- and HIF1αmu (hypoxia-inducible factor 1 mutation)-
expressing BMSCs (bone marrow mesenchymal stem cells) on the bone defect repair.
Methods: (1) BMSCs were infected with viral solution containing BMP2 and HIF1αmu with the best MOI
(multiplicity of infection). The efficiency was observed via hrGFP (human renilla reniformis green fluorescent
protein). (2) The cells were divided into five groups (A–E), and ALP (alkaline phosphatase) activity was measured.
(3) BMP2 and HIF1α (hypoxia-inducible factor 1α) protein were measured. (4) A-W MGC was loaded with BMSCs
that contain the genes and implanted into the bone defect model. The animals were sacrificed 8 and 12 weeks
later. (5) The healing was measured with X-ray, histology, and biomechanics.
Results: (1) BMSCs in A–D showed high transfection efficiency. (2) ALP in A and B was higher than the others
(p = 0.041 or 0.038); A was higher than B (p = 0.038); (3) BMP2 in A and B was higher than the others (p = 0.014).
HIF1α in A and C was higher than the others (p = 0.020). (4) 8 and 12 weeks after, an X-ray indicated that bone defect
was nearly fully repaired in A and C. (5) 12 weeks after, the bone remodeling was complete in A and C. (6) The flexural
strength in A and C was stronger than the others (p = 0.043).
Conclusion: Engineered A-W MGC with BMP2 and HIF1αmu-expressing BMSCs exhibits comparable therapeutic effects
of bone-defect repair as an autologous bone graft.
Keywords: Bone defects, Bone marrow mesenchymal stem cells, Bone morphogenetic protein 2, Hypoxia-inducible
factor 1αBackground
Treatment of large bone defects caused by trauma has
been a major unsolved problem in the orthopedics field
[1, 2]. Clinically, bone grafts have remained the standard
treatment to restore the integrity and biomechanical
properties of the bone defects. The breakthrough in cre-
ating a new type of engineered bone grafts, which com-
bine the osteogenic factors, osteogenic stem cells, and
the artificial bone scaffold, provides a new way for the
bone-defect treatment.* Correspondence: guangyufancmd@sina.com
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unless otherwise stated.BMP (bone morphogenetic protein) is one of the
osteogenic factors that play important roles in the
ontogenesis. BMP can stimulate the differentiation of
mesenchymal cells into osteogenic cells and enhance
osteoblasts [3], which initiates a series of bone regener-
ation steps to improve bone healing. However, due to the
damage of the blood vessels of the microcirculation sys-
tem at the injury site, it is difficult to rebuild a vascular
system in the core part of the large engineered bone
graft (diameter >5 mm), resulting in poor bone growth
and the failure of bone graft transplantation. Meanwhile,
the transfected osteogenic cells stop growing due to
insufficient nutrient supply, resulting in the difficulty of
new bone formation inside the engineered bone graft.
Therefore, it is critical to build an effective network ofis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Reagents
Name Company
Adv-HIF1αmu-hrGFP (1.6 × 108 pfu/mL) First Affiliated Hospital of
Liaoning Medical Tissue
Engineering Laboratory
Adv-BMP2-hrGFP (2.0 × 108 pfu/mL) First Affiliated Hospital of
Liaoning Medical Tissue
Engineering Laboratory
Rabbit anti-human HIF1α monoclonal
antibody, rabbit anti-human BMP2
monoclonal antibody
Secondary antibodies, β-actin Santa Cruz, USA
DMEM (low glucose, catalog number:
10567-014), trypsin, fetal bovine serum
Gibco, USA




ALP kit TaKaRa, Japan




HIF1αmu hypoxia-inducible factor 1 mutation, hrGFP human renilla reniformis
green fluorescent protein, BMP2 bone morphogenetic protein 2, ALP alkaline
phosphatase, A-W MGC apatite-wollastonite magnetic bioactive glass-ceramic
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and form sufficient connections with the blood vessels in
the host bones to provide nutritional and metabolic sup-
ply and stimulate osteogenic differentiation, thereby pro-
moting healing and repair of bone defects.
Angiogenesis is regulated by a series of growth factors
[4–6]. Because HIF1α (hypoxia-inducible factor 1α) plays
an important role in promoting angiogenesis, it is con-
sidered the most promising gene in the clinical applica-
tion [7–11]. However, HIF1α can only be expressed and
accumulated under hypoxic conditions. The 402 and 564
proline in the ODDD (oxygen-dependent degradation
domain) in the CDS (coding sequence) cannot be
hydroxylated, which causes the rapid degradation (within
minutes) of the endogenous HIF1α [12–15]. Lando et al.
have reported [16] that the transcriptional activity of
HIF1α can be reduced by the function of the 803 aspara-
gine in the CDS area, suggesting that the 402 and 564
proline and the 803 asparagine in the CDS area are im-
portant loci of HIF1α. In our previous research, we have
created HIF1αmu (hypoxia-inducible factor 1 mutation),
which not only can be expressed under normoxic condi-
tion in vitro but also can promote angiogenesis in the
bone-defect area under normoxic conditions in vivo
[17]. In this current study, we constructed engineered
bone graft using A-W MGC (apatite-wollastonite mag-
netic bioactive glass-ceramic) combined with BMSCs
that are co-infected with adenovirus vectors containing
HIF1αmu and BMP2 genes. Our goal is to explore the
interaction of HIF1αmu and BMP2 and the impact on
angiogenesis and ontogenesis in bone-defect area.
Materials and methods
Materials
The reagents used in this study are shown in Table 1.
Animals
Sixty-one purebred New Zealand white rabbits, 3–4
months of age, weighing 2.0–2.8 kg, male or female, were
provided by the Experimental Animal Center of Liaoning
Medical University. All experimental procedures were car-
ried out in accordance with the experimental animal and
animal welfare requirements of Liaoning Medical Experi-
ments Animal Ethics Committee.
Methods
Infection of BMSCs with recombinant adenovirus
The New Zealand white rabbit was deeply anesthetized,
and the bone marrows from the right tibial bone were
harvested. BMSCs were isolated, purified, and cultured
to the third generation. The infections of Adv-HIF1αmu-
hrGFP and Adv-BMP2-hrGFP were carried out with the
best MOI (multiplicity of infection): MOI = 100 (HIF1α)
and MOI = 150 (BMP2). The infection efficiency wasevaluated with inverted fluorescence microscope 72 h
after the infection.
Experimental groups
Group A: BMSCs were infected with viral solution
containing Adv-BMP2-hrGFP and Adv-HIF1αmu-
hrGFP.
Group B: BMSCs were infected with viral solution
containing Adv-BMP2-hrGFP.
Group C: BMSCs were infected with viral solution
containing Adv-HIF1αmu-hrGFP.
Group D: BMSCs were infected with viral solution
containing Adv-hrGFP.
Group E: BMSCs without infection of any viral
solution.
Detection of the cell ALP activity and concentration
The supernatant in 96-well culture plates was removed
3, 6, 9, and 12 days after infection; the cells were
washed once with PBS. The number of cells per well
was estimated and adjusted to a similar value for each
well. 100 μL 0.1 % Triton X-100 was added to each well
and incubated at 4 °C overnight. All procedures were
carried out according to the manufacturer’s instruc-
tions. The absorbance change per minute (ΔA/min)
was measured at 405 nm and monitored for three con-
secutive minutes. The ALP (alkaline phosphatase) activ-
ity (U/L) = ΔA/min × 2757.
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Western blot
The total protein from each group was extracted using
lysis buffer and the protein concentration was mea-
sured by BCA assay. Equal amounts of total protein
from each group were separated by SDS-PAGE (5 and
8 %), 60 V × 30 min, 150 V × 1 h. After three washes, the
proteins were transferred to PVDF membranes (100 mA
× 30 min). The membranes were incubated with primary
antibodies (1:1500) at 4 °C overnight. The membranes
were washed and incubated with secondary antibodies
and developing solution in a dark room for 30 min at
room temperature. The membranes were washed three
times with triple-distilled water to terminate the color
reaction. The target bands on the membranes were ana-
lyzed by gel imaging system with the reference OD values.
The experiment was repeated three times to calculate the
relative OD values.Fig. 1 The green fluorescence expressions in each group (×200). a BMSCs th
that were infected with Adv-BMP2-hrGFP. c BMSCs that were infected with A
without infection. BMSCs: mesenchymal stem cells. BMP2: bone morphogene
HIF1αmu: hypoxia-inducible factor 1 mutationProduction of bone-defect animal model
Pre-operative treatment of biological scaffolds
A-W MGC biological scaffolds, 1.5 cm length, 0.5 cm
diameter, were sterilized, surface prepared, and dried.
Seventy-two hours after viral infection, the BMSCs were
suspended at a density of 2 × 107/mL and then trans-
planted into A-W MGCs, 5 × 106 each side. The A-W
MGCs were rocking cultured at 37 °C, 5 % CO2 for
48 h, and the cells were evenly and fully adhered to the
internal space of the biological scaffolds.
Animal model of bone defects
New Zealand white rabbits were anesthetized and a 1.5-
cm segment from the middle section of the right radius
was removed to create a bone-defect region. The pre-
treated A-W MGCs were anastomosed end-to-end to
the stumps of the broken bones. After the surgery, the
animals were given intramuscular injection of antibioticsat were infected with Adv-BMP2-hrGFP and Adv-HIF1αmu-hrGFP. b BMSCs
dv-HIF1αmu-hrGFP. d BMSCs that were infected with Adv-hrGFP. e BMSCs
tic protein 2. hrGFP: human renilla reniformis green fluorescent protein.
Fig. 2 The ALP concentration at different time points in each BMSC
group. a BMSCs that were infected with Adv-BMP2-hrGFP and Adv-
HIF1αmu-hrGFP. b BMSCs that were infected with Adv-BMP2-hrGFP.
c BMSCs that were infected with Adv-HIF1αmu-hrGFP. d BMSCs that
were infected with Adv-hrGFP. e Blank control BMSCs (no infection).
ALP: alkaline phosphatase. BMSCs: mesenchymal stem cells. BMP2:
bone morphogenetic protein 2. hrGFP: human renilla reniformis green
fluorescent protein. HIF1αmu: hypoxia-inducible factor 1 mutation
Gao et al. Journal of Orthopaedic Surgery and Research  (2015) 10:83 Page 4 of 10for 7 days. The animals’ daily activities and wound
healing process were closely monitored. Animals were
sacrificed 8 and 12 weeks after the surgery. All ani-
mal models were produced by the same operator.
Experimental groups
Sixty New Zealand white rabbits were randomly divided
into A, B, C, D, and E groups of 12.
Group A: A-W MGC transplanted with BMSCs
that were infected with Adv-HIF1αmu-hrGFP and
Adv-BMP2-hrGFP.
Group B: A-W MGC transplanted with BMSCs that
were infected with Adv-BMP2-hrGFP.
Group C: autogenous bone graft group (contralateral
radial transplantation).
Group D: A-W MGC transplanted with BMSCs that
were infected with Adv-HIF1αmu-hrGFP.
Group E: A-W MGC scaffold alone.
X-ray observation
Eight or 12 weeks after surgery, the animals were anes-
thetized and the x-ray images of the radius and ulna at
the ipsilateral site of surgery were taken. Projection
conditions were 40 kV, 50 mA, 0.2 s, and a projection
distance of 60 cm.
Histological examination
The animals in each group were sacrificed 12 weeks
after the surgery. The radius and ulna at the bone-defect
area were harvested. The degradation of the implant
graft, the functional connection between the graft and
the host bone, and the surrounding soft tissue response
were observed. The tissues from the center of the bone-
defect area were decalcified in 5 % nitric acid for 72 h,
fixed in 4 % formalin, paraffin-embedded, and sliced
continuously with a thickness of 10 μm. HE staining was
performed.
Biomechanical measurement
Twelve weeks after the surgery, the samples from each
group were tested with a universal testing machine (AG-
IC, SHIMADZU) for anti-flexion strength with a span of
30 mm and a loading rate of 0.5 mm/min. The flexural
strength of new bones at the bone-defect area in each
group was compared.
Statistical analysis
SPSS 18.0 for Windows software package was used for
statistical analysis. Data were expressed as mean ± stand-
ard deviation (x ± s). One-way ANOVA was used for the
comparisons among groups (normally distributed data).
Non-parametric statistics (Wilcoxon rank-sum test) wereused for analyzing non-normally distributed data. p < 0.05
was considered statistically significant.Results
BMSCs were successfully infected with recombinant
adenovirus
The BMSCs in groups A, B, C, and D showed strong
expressions of green fluorescent protein under a fluores-
cence microscope 72 h after infection. The number of
BMSCs expressing green fluorescent protein was high,
indicating the efficient infection rate (Fig. 1).ALP activity in each cell group
ALP activity was detected according to the manufac-
turer’s instructions. The absorbance change per minute
(ΔA/min) was measured at 405 nm and monitored for
three consecutive minutes. The ALP activity (U/L) =
ΔA/min × 2757. The ALP in group A was significantly
higher than the B, C, D, and E groups (p = 0.038). The
ALP in group B was significantly higher than the C, D,
and E groups (p = 0.041). There was no significant dif-
ference among C, D, and E groups (p = 0.926) (Fig. 2
and Table 2).
Table 2 The measurement of ALP in each BMSC group at
different time points (U/L, N = 8, x ± s)
Group 3 days 6 days 9 days 12 days
A 28.74 ± 1.37 37.89 ± 1.73 42.87 ± 2.38 45.12 ± 2.22
B 21.18 ± 1.34* 26.91 ± 3.62* 32.12 ± 2.41* 33.79 ± 2.57*
C 14.27 ± 0.73*# 15.94 ± 1.26*# 16.36 ± 1.28*# 17.15 ± 0.74*#
D 12.99 ± 0.62*# 16.39 ± 0.95*# 16.71 ± 1.08*# 18.01 ± 1.24*#
E 13.38 ± 0.85*# 16.21 ± 1.08*# 16.54 ± 1.23*# 17.08 ± 0.91*#
ALP alkaline phosphatase, BMSCs bone marrow mesenchymal stem cells
*Compared with group A, p < 0.05; #compared with group B, p < 0.05
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group
The BMP2 protein expression was significantly higher in
the A and B groups, compared with groups C, D, and E
(p = 0.014). The BMP2 protein expression was slightly
higher in group A than group B; however, the difference
was not significant (p = 0.069). The HIF1α protein ex-
pression was significantly higher in the A and C groups,
compared with groups B, D, and E (p = 0.020). There
was no significant difference among groups B, D, and E,
indicating that mutant HIF1α can express functionalFig. 3 The BMP2 and HIF1α protein expressions in the five BMSC groups. a
hrGFP. b BMSCs that were infected with Adv-BMP2-hrGFP. c BMSCs that w
Adv-hrGFP. e Blank control BMSCs (no infection). BMSCs: mesenchymal stem
reniformis green fluorescent protein. HIF1αmu: hypoxia-inducible factor 1 mproteins under normoxic conditions, whereas wild type
HIF1α cannot exist under normoxic conditions (Fig. 3).
X-ray examination
Eight weeks after the surgery, the bone intensity in the
bone-defect area in group A (double gene infection
group) and group C (autogenous bone graft group) sig-
nificantly increased, similar to the normal bone tissue;
the fracture line was barely visible, and bone defect was
completely reconnected. In group B, the new bone callus
increased, but the fracture line at both ends was still vis-
ible and the bone defect has not been fully reconnected.
In group D, there was a small amount of callus forma-
tion, but the bone defect has not been fully reconnected
and the fracture line at both ends was clearly visible. In
group E, the implant material and the fracture line were
clearly visible without signs of absorption of the implant
material (Fig. 4). Twelve weeks after the surgery, the
bone defect was completely repaired in group A and
group C, the bone structure was improved, and the bone
density was similar to the normal bone tissue. The
cortical and medullary cavity structures were visible. In
group B, the bone density in the defect area wasBMSCs that were infected with Adv-BMP2-hrGFPand Adv-HIF1αmu-
ere infected with Adv-HIF1αmu-hrGFP. d BMSCs that were infected with
cells. BMP2: bone morphogenetic protein 2. hrGFP: human renilla
utation
Fig. 4 X-ray showed the bone-defect areas in different groups at 8 weeks after the surgery. a A-W MGC transplanted with BMSCs that were
infected with Adv-HIF1αmu-hrGFP and Adv-BMP2-hrGFP. b A-W MGC transplanted with BMSCs that were infected Adv-BMP2-hrGFP. c autogenous
bone graft group. d A-W MGC transplanted with BMSCs that were infected with Adv-HIF1αmu-hrGFP. e A-W MGC. Arrows: defect sites. MGC: magnetic
bioactive glass-ceramic. BMSCs: mesenchymal stem cells. BMP2: bone morphogenetic protein 2. hrGFP: human renilla reniformis green fluorescent
protein. HIF1αmu: hypoxia-inducible factor 1 mutation
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defect repair and remodeling were slow. In group E,
there was sclerosis, with no bone-defect repair or visible
bone marrow cavity (Fig. 5).Histological observation
Twelve weeks after the surgery, the A-W MGC graft
was completely degraded in group A. The new bone
tissues showed mature bone structure and visible tra-
beculae. In group B, the bone defect was reconnected,
but there was still residual carrier scaffold indicating
the degradation was incomplete. In group C, the cor-
tex and medulla of the bone defect were completely
reconnected. The bone remodeling and healing were
complete. In group D, there were less trabecular bones
and the carrier material was not absorbed. In group E,
there was clear bone defect, poor reconnection, and
visible fibrous connective tissue filling (Fig. 6).Biomechanical test (flexural strength test)
The results of flexural strength test from each group were
as follows: group A, 107.59 ± 4.91 MPa; group B, 82.34 ±
5.03 MPa; group C, 112.94 ± 6.08 MPa; group D, 52.41 ±
4.26 MPa; group E, 33.27 ± 4.55 MPa. There was no
significant difference between A and C groups (p = 0.88).
There were significant differences between all the other
two-group comparisons (p = 0.043) (Fig. 7).
Discussion
In this study, we used A-W MGC scaffold loaded with
BMSCs that were infected with BMP2 and HIF1αmu
genes for the treatment of in vivo bone defects and
achieved therapeutic effects that were comparable with
an autogenous bone graft. Firstly, the successful reestab-
lishment of microcirculation system at the bone-defect
site not only provides osteoblasts with nutrition but also
has anti-apoptotic effects. Therefore, it will promote the
stable growth of osteoblasts, accelerate bone healing
Fig. 5 X-ray showed the bone-defect areas in different groups at 12 weeks after the surgery. a A-W MGC transplanted with BMSCs that were infected
with Adv-HIF1αmu-hrGFP and Adv-BMP2-hrGFP. b A-W MGC transplanted with BMSCs that were infected Adv-BMP2-hrGFP. c autogenous bone graft
group. d A-W MGC transplanted with BMSCs that were infected with Adv-HIF1αmu-hrGFP. e A-W MGC. Arrows: defect sites. MGC: magnetic bioactive
glass-ceramic. BMSCs: mesenchymal stem cells. BMP2: bone morphogenetic protein 2. hrGFP: human renilla reniformis green fluorescent protein.
HIF1αmu: hypoxia-inducible factor 1 mutation
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planted bone graft [18–20]. Secondly, a single factor
may not be able to sufficiently repair the damages to the
systems caused by the bone defect; in this case, it might
be more sufficient to apply multiple genes to achieve
individualized repair on different systems. Therefore, this
experiment not only provides the foundation for the
treatment of bone defects using multigene therapy, but
also offers new ideas to broaden the gene therapy in
other ischemic diseases.
HIF1α and BMP2 as the target genes
The key point in the gene therapy of bone defects is
to introduce the osteogenic factors into the seed cells
used for the tissue engineered bone graft. These seed
cells can continue to proliferate in vivo and secret
growth factors to promote fracture healing [21]. Among
these osteogenic factors, BMP2 has the most significant
effect on the bone regeneration [22–24]. Therefore, weused an adenovirus vector carrying BMP2 gene to infect
BMSCs in order to achieve a sustained localized expres-
sion of bone morphogenetic protein to accelerate fracture
healing.
Local application of angiogenic factors has been a
part of the adjuvant treatment in bone-defect diseases
and has not received much attention for the past
years. However, people start to realize that it is equally
important to establish a local blood circulation to pre-
vent the death of osteoblasts after transplantation. HIF1α
is a transcription factor generated under hypoxic condi-
tions and is sensitive in the detection of local tissue
hypoxia. The concentration of HIF1α increases with pro-
longed hypoxia and decreases rapidly after the improve-
ment of hypoxia [25]. Under the temporary anoxic
conditions, HIF1α not only can maintain the survival of
osteoblasts but also can neutralize the harmful sub-
stances produced by hypoxic cells, creating a favorable
osteogenic microenvironment [25]. Therefore, HIF1α is
Fig. 6 HE staining images (×100) from different groups 12 weeks after surgery. a A-W MGC transplanted with BMSCs that were infected with
Adv-HIF1αmu-hrGFP and Adv-BMP2-hrGFP. b A-W MGC transplanted with BMSCs that were infected Adv-BMP2-hrGFP. c Autogenous bone graft
group. d A-W MGC transplanted with BMSCs that were infected with Adv-HIF1αmu-hrGFP. e A-W MGC. Arrows: cell nuclei. HE: hematoxylin and
eosin. A-W MGC: apatite-wollastonite magnetic bioactive glass-ceramic. BMSCs: mesenchymal stem cells. BMP2: bone morphogenetic protein 2.
hrGFP: human renilla reniformis green fluorescent protein. HIF1αmu: hypoxia-inducible factor 1 mutation
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(vascular endothelial growth factor). To date, no report
has been found on the effects of HIF1α combined with
BMP2 multigene therapy in bone-defect diseases. HIF1α
cannot stably express under normoxic conditions. To
overcome this shortcoming, we have successfully con-
structed a triple mutant HIF1α by point mutation of the
402,564 and 803 amino acids without affecting other func-
tional areas. The triple point-mutant HIF1α can express
functional protein under normoxic conditions and play
important physiological roles in angiogenesis [17].
The interaction between HIF1α and BMP2
The increase of ALP concentration is a specific marker
indicating the differentiation of BMSCs into osteoblasts.
In order to analyze the impact of HIF1αmu on BMP2
expression, we measured the ALP from BMSCs that
were infected with HIF1αmu plus BMP2, the BMSCs that
were infected with only BMP2, and the BMSCs withoutinfection at 3, 6, 9, and 12 days after infection. We found
that the ALP activity significantly increased in the
BMSCs that were infected either with HIF1αmu plus
BMP2 or with only BMP2, compared with uninfected
BMSCs. Compared with the BMSCs that were infected
with only BMP2, the ALP activity in the BMSCs that
were infected with HIF1αmu plus BMP2 was significantly
higher (p < 0.05), suggesting that HIF1αmu can promote
BMP2 expression and increase ALP level.
The advantages of A-W MGC as a scaffold
An ideal artificial scaffold should have the following
characteristics [26]: 1) has good biocompatibility (with-
out inflammation with host tissue) and is biodegradable;
2) has excellent osteoinductive and osteoconductive ef-
fects; and 3) can provide good osteogenic environment
to support the growth of seed cells. A-W MGC scaffold
used in this experiment was made of bioactive ceramics
and has a stronger cell adhesion by a surface treatment
Fig. 7 The results of flexural strength test from each group. a A-W
MGC transplanted with BMSCs that were infected with Adv-HIF1αmu-
hrGFP and Adv-BMP2-hrGFP. b A-W MGC transplanted with BMSCs
that were infected Adv-BMP2-hrGFP. c Autogenous bone graft
group. d A-W MGC transplanted with BMSCs that were infected with
Adv-HIF1αmu-hrGFP. e A-W MGC. A-W MGC: apatite-wollastonite
magnetic bioactive glass-ceramic. BMSCs: mesenchymal stem cells.
BMP2: bone morphogenetic protein 2. hrGFP: human renilla reniformis
green fluorescent protein. HIF1αmu: hypoxia-inducible factor 1
mutation
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μm pores, and these well-interconnected pores favor the
cell adhesion and proliferation, promote angiogenesis
and blood vessel network formation, and accelerate the
merge of new bone and bio-material. Therefore, A-W
MGC exhibits good biocompatibility, osteoconductive/
osteoinductive effects, and degradability [27], meets the
requirements for bone tissue engineering material, and
becomes the preferred carrier scaffold.
The new tissue engineered bone graft achieved
comparable therapeutic effects as the autologous bone
graft
X-ray results indicate that the bone formation and bone
remodeling capabilities in group A (A-W MGC seeded
with BMSCs that were infected with HIF1αmu plus BMP-2)
were similar with group C (autogenous bone graft group)
(p > 0.05). Meanwhile, the bone formation and bone
remodeling capabilities in A and C groups were superior to
the other groups.
In this study, HE staining was used to observe the
degradation of the implant materials, the graft-host
bone interface, and the surrounding soft tissue reac-
tions. Histological results indicate that A-W MGC ingroup A was fully degraded 12 weeks after surgery and
the new mature bone tissues and trabecular bones were
more visible. The healing of bone defect was similar
compared with group C, whereas the osteogenic effect
was not very obvious in the other three groups.
Flexural strength test is the most convincing indicator
for the mechanical properties of bone formation. The
change in the morphology and mechanical properties of
bone tissue by the external force is a reliable method for
the evaluation of osteogenic effects. The results from bio-
mechanical testing 12 weeks after surgery indicate that
the engineered bone graft in group A had similar effects
on the bone regeneration in the bone-defect area com-
pared with autogenous bone graft, whereas the osteogenic
effect from the other groups were much less effective.
Conclusion
In the present study, we constructed A-W MGC bone
graft loaded with BMSCs that were infected with both
HIF1αmu and BMP2. The angiogenic effects of HIF1αmu
and the osteogenic effects of BMP2 interacted with
each other, promoted the healing process of the bone
defect, and achieved similar results as autologous bone
graft. These results indicate that this A-W MGC bone
graft will be an ideal alternative for autologous bone
graft and solve the problems due to the insufficient
number of autologous bone grafts and the complications
of autologous bone transplantation. However, angiogen-
esis and ontogenesis are extremely complex physiological
processes. The introduction of the exogenous triple point-
mutant HIF1α and BMP2 genes promotes the formation
of blood vessel network and bone regeneration; how-
ever, the interaction of these exogenous genes with the
endogenous angiogenic and osteogenic factors is still
unknown. The impact of the mutation on the function
of HIF1α itself and BMP2, as well as the function of
the three alanine mutations in the angiogenic process,
needs to be further explored in our future studies.
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